Loader
Loading Pathway...
Myosin light chain kinase, smooth muscle 5- hydroxytryptamine receptor 1B Guanine nucleotide- binding protein G(i) subunit alpha-1 Guanine nucleotide- binding protein G(I)/G(S)/G(T) subunit beta-1 Gγ Adenylate cyclase type 5 PKA complex PKA complex Myosin LC-P Myosin light chain 3 Voltage- dependent P/Q-type calcium channel subunit alpha-1A Voltage- dependent L-type calcium channel subunit beta-1 Voltage- dependent calcium channel subunit alpha-2/delta-2 Serine/threonine- protein phosphatase PP1-beta catalytic subunit Calmodulin-1 Calmodulin-1 cAMP Frovatriptan Ca+ Ca+ ATP ATP PPi Ca+ Muscle Contraction Muscle Relaxation Vasoconstriction Magnesium Calcium Manganese Myosin binds from actin causing the sarcomere filaments to slide leading to smooth muscle contraction and vasoconstriction Increased calcium binds readily to calmodulin to activate myosin light chain kinase Reduced protein kinase A (PKA) activity is generally associated with increased intracellular calcium concentration and the activation of myosin light chain kinase (MLCK), all of which contribute to smooth muscle contraction and blood vessel constriction. Cytosol Activation of myosin light chain kinase leads to high concentration of myosin LC-P which causes contractions of the muscles Vascular Smooth Muscle Cell Constriction Frovatriptan is an agonist at 5-HT1B and1D receptors present on smooth muscles within the blood vessels and peripheral terminals of the trigeminal nerve innervating cranial blood vessels Actin Filament Myosin Filament Frovatriptan is administered as an oral pill Lower PKA activity leads to decreased phosphorylation of certain proteins, including myosin light chain (MLC), in smooth muscle cells. Reduced MLC phosphorylation promotes the activation of myosin light chain kinase (MLCK). Decreased cAMP levels can lead to increased intracellular calcium concentration by various mechanisms, including the release of calcium from intracellular stores. Frovatriptan decreases carotid arterial blood flow, but increases blood flow velocity in the internal carotid artery and middle cerebral artery Cranial blood vessels Brain
MYLK HTR1B GNAI1 GNB1 GNG2 ADCY5 PRKAR1A PRKAR2A MYL3 MYL3 CACNA1A CACNB1 CACNA2D2 PPP1CB CALM1 CALM1 cAMP Frovatriptan Calcium Calcium Adenosine triphosphate Adenosine triphosphate Pyrophosphate Calcium Muscle Contraction Muscle Relaxation Vasoconstriction
MYLK HTR1B GNAI1 GNB1 GNG2 ADCY5 PRKAR1A PRKAR2A MYL3 MYL3 CACNA1A CACNB1 CACNA2D2 PPP1CB CALM1 CALM1 cAMP Frovatr Ca+ Ca+ ATP ATP PPi Ca+ Mus Con Mus Rel Vasoc Mg2+ Ca2+ Mn2+ Myosin binds from actin causing the sarcomere filaments to slide leading to smooth muscle contraction and vasoconstriction Increased calcium binds readily to calmodulin to activate myosin light chain kinase Reduced protein kinase A (PKA) activity is generally associated with increased intracellular calcium concentration and the activation of myosin light chain kinase (MLCK), all of which contribute to smooth muscle contraction and blood vessel constriction. Cytosol Activation of myosin light chain kinase leads to high concentration of myosin LC-P which causes contractions of the muscles Vascular Smooth Muscle Cell Constriction Frovatriptan is an agonist at 5-HT1B and1D receptors present on smooth muscles within the blood vessels and peripheral terminals of the trigeminal nerve innervating cranial blood vessels Actin Filament Myosin Filament Frovatriptan is administered as an oral pill Lower PKA activity leads to decreased phosphorylation of certain proteins, including myosin light chain (MLC), in smooth muscle cells. Reduced MLC phosphorylation promotes the activation of myosin light chain kinase (MLCK). Decreased cAMP levels can lead to increased intracellular calcium concentration by various mechanisms, including the release of calcium from intracellular stores. Frovatriptan decreases carotid arterial blood flow, but increases blood flow velocity in the internal carotid artery and middle cerebral artery Cranial blood vessels Brain
MYLK HTR1B GNAI1 GNB1 GNG2 ADCY5 PRKAR1A PRKAR2A MYL3 MYL3 CACNA1A CACNB1 CACNA2D2 PPP1CB CALM1 CALM1 cAMP Frovatr Ca2+ Ca2+ ATP ATP Ppi Ca2+ Mus Con Mus Rel Vasoc